
Qiagen N.V.
Qiagen N.V. is a Netherlands-based company in the Healthcare sector with a market capitalisation of $9.5B. Its FinScore is 69/100; its highest-scoring layer is Quality (82) and its lowest is Growth (47). The shares trade at 23.2x trailing earnings and are down 3% year to date.
Share price performance
About Qiagen N.V.
www.qiagen.comQiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- HQ
- Netherlands
- Fiscal year-end
- December
- Trading currency
- USD
- Reporting currency
- USD
- Fundamentals updated
- 71 days ago
- Market cap
- $9.5B
- Shares outstanding
- 206.1M
- P/E (TTM)
- 23.2x
- Dividend yield (TTM)
- 0.76%
- Beta (issuer)
- 0.61
- Revenue (latest FY)
- $2.1B
Revenue breakdown
- Diagnostic Solutions37.9%$748.9M
- Sample Technologies32.5%$642.0M
- PCR / Nucleic Acid Amplification15.2%$300.5M
- Genomics / NGS11.8%$233.6M
- Product and Service, Other2.7%$53.2M
FinScore
As of 2026-10-19Snapshot
Ownership
As of 2026-06-30Sign up or log in to see Analysis
Analysis for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Financials
Financials for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Estimates
Estimates for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Peers
Peers for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see Valuation
Valuation for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.
Sign up or log in to see News
News for Qiagen N.V. is available to Finryse members. The Overview stays open to everyone; creating an account is free.